letrozole has been researched along with Depression, Endogenous in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Developing depressive disorders are at higher risk in breast cancer survivors aged 40-59 who received adjuvant treatments including chemotherapy, radiotherapy, tamoxifen, AIs or trastuzumab." | 3.81 | Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study. ( Chang, CH; Chen, SJ; Liu, CY, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CH | 1 |
| Chen, SJ | 1 |
| Liu, CY | 1 |
1 other study available for letrozole and Depression, Endogenous
| Article | Year |
|---|---|
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; C | 2015 |